Microbiome-Based Therapeutics
News Release, International Society of Microbiota, France – March 25, 2022
Symbiotic microorganisms inhabiting the gastrointestinal tract promote health by decreasing susceptibility to infection and enhancing resistance to a range of diseases.
In this review, Sorbara et al, discuss the increasing understanding of the impact of the microbiome on the mammalian host and recent efforts to culture and characterize intestinal symbiotic microorganisms that produce or modify metabolites that impact disease pathology. They review the classes of microbiome-based therapeutics in detail and discuss clinical trials all in one paper.
Classes of microbiome-based therapeutics.
Manipulation of the intestinal microbiome has great potential to reduce the incidence and/or severity of a wide range of human conditions and diseases, and the biomedical research community now faces the challenge of translating our understanding of the microbiome into beneficial medical therapies. The increasing understanding of symbiotic microbial species and the application of ecological principles and machine learning are providing exciting opportunities for microbiome-based therapeutics to progress from faecal microbiota transplantation to the administration of precisely defined and clinically validated symbiotic microbial consortia that optimize disease resistance.
In Targeting Microbiota 2022 a whole session will be dedicated to "Role of Microbiota in Drugs Metabolism: Towards Personalized Medicine". Remember you can submit your abstracts under this title and share your work with the International Society of Microbiota. Details on abstract submission.
Media contact:
International Society of Microbiota
microbiota@microbiota-ism.com
Targeting Microbiota 2022 Congress
October 19-21, 2022 - Paris, France
www.microbiota-site.com
